La Jolla Institute for Allergy & Immunology Wows With New Website

LOS ANGELES, April 11 /PRNewswire/ -- Specto Design (www.spectodesign.com ), a leading Los Angeles branding and web design company has reinvented the website for a world renowned biomedical research institute. (www.liai.org )

"This is a great example of how to open up the content to the user with high-impact visuals and user-centric content, to create awareness while also conveying La Jolla Institute for Allergy & Immunology's dedication to 'Finding Cures Faster' in a very exciting way," said Axel Muench, creative director and principal at Specto Design. "This website is a stunning journey through the possibilities and accomplishments of biomedical research in the fields of allergy & immunology."

The new website is reflective of the collaboration-based environment at the Institute, and will now be used as both an information portal and a marketing and fundraising tool. "We are so impressed by the Specto Design creative team. The reorganized content on the site and superior visual impact reflects our cutting-edge research. Specto really hit the mark for us," said Erin Righetti, development officer at the Institute.

About the La Jolla Institute for Allergy & Immunology: Founded in 1988, the La Jolla Institute for Allergy & Immunology (LIAI) is one of only a few non-profit research institutions in the world focused on understanding the immune response to infectious agents and cancers and on advancing progress toward the prevention, treatment and cure of immune system diseases.

This release was issued through WebWire(R). For more information visit http://www.webwire.com.

SOURCE Specto Design - Los Angeles Web Design

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.